Xspray-logo-white
  • About us
    • Board of Directors & Board committees
    • Management
    • Our history – a timeline
  • The Technology
    • Equal but better
    • Technology: in-depth
  • Business model
    • The patent window
    • Product candidates
    • Patents and other immaterial rights
  • Media
  • Contact
  • Investors
  • en en
    • sv sv
  • Investors
    • Share information
      • Trading information
      • Ownership structure
    • Financial calendar & Events
    • Financial reports
    • Prospectus
    • Press releases
    • Corporate governance
      • Corporate Structure
      • General meetings
      • Corporate Governance Reports
      • Nomination committee
      • Board of Directors & Board committees
      • Management
      • Accounting principles
      • Internal control & Risk management
      • Auditor
      • Articles of association

Press releases

All press releases Regulatory

Regulatory press release 2021-01-22

Xspray Pharmas study with modified formulation of HyNap-Dasa has now started

Regulatory press release 2021-01-14

Xspray Pharma announces results from additional bioequivalence study and provides update regarding upcoming regulatory applications for ANDA and 505(b)(2)

Press release 2020-12-30

Xspray Pharma reports positive results from a study with dasatinib during omeprazole treatment

Regulatory press release 2020-12-29

Xspray Pharma’s HyNap-Nilo receives FDA Orphan Drug Designation for the treatment of Chronic Myeloid Leukemia

Press release 2020-12-17

Xspray Pharma moves up to Nasdaq Stockholm’s Mid Cap-segment

Regulatory press release 2020-12-11

Xspray Pharma has decided to await the result of two ongoing clinical studies before submitting its ANDA application

Regulatory press release 2020-11-20

Xspray Pharma publishes Interim Report Q3, January – September 2020

Regulatory press release 2020-10-30

Number of shares and votes in Xspray

Press release 2020-10-21

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2021

Regulatory press release 2020-10-20

Xspray Pharma Has Carried Out a Directed Share Issue Raising Gross Proceeds of Approximately SEK 265 million

Show more

Subscribe

  • Submit to our press releases and get an email every time we publish a press release or report on our website.
  • When clicked on Send I agree that my personal information will be saved. Read more
  • This field is for validation purposes and should be left unchanged.
Xspray-logo-white

Xspray Pharma AB Råsundavägen 12 169 67 Solna

+46 (0)8 730 37 00 info@xspraypharma.com

We use cookie to give you the best experience of our site. If you continue to use this website we will assume you agree. Read more about our integritetspolicy.I agree